Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (729)	10/25/2002 4:17:48 PM
From: keokalani'nui	Read Replies (1) of 1005

Yes dov unlocked on the 22nd. I counted the days, twice. There has been absolutely no overhead supply, not even into a modestly climbing price. But then really, at $4/share you are close to valuations set by the last venture round (most of elan's stock/warrants are priced at $3.98); and since the ipo, you have bicifadine results (and elan's technology being approved in avistin, right?), indiplone patent and clinical progress all producing a bone-jarring minus 69% return. There is surely a lot of overhang coming but either at higher prices or upon disappointing news. Or so it seems.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next